# Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax

Source: https://onco.cc/trials/nct01081951/  
OnCo record `nct01081951` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Olaparib, Paclitaxel / nab-paclitaxel, Carboplatin in ovarian cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer is a phase 2 interventional study registered as NCT01081951 by AstraZeneca, with 162 participants enrolled, started 2010-02-04 and due to reach its primary completion in 2011-10-10. Interventions recorded: olaparib, paclitaxel, carboplatin, paclitaxel, Drug: carboplatin. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT01081951
- Phase: 2
- Setting: A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer
- Sponsor: AstraZeneca
- Enrolled: 162

## Sources

- ClinicalTrials.gov NCT01081951: https://clinicaltrials.gov/study/NCT01081951

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Olaparib](https://onco.cc/drugs/olaparib/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct01081951.json